MADIT

Also found in: Acronyms.

MADIT

Cardiology A clinical trial–Multicenter Automatic Defibrillator Implantation Trial that evaluated the effects of implanted defibrillators–IDs in Pts with CAD at high risk of ventricular arrhythmia

Mentioned in ?

References in periodicals archive ?

A regression analysis on patients from the MADIT II (13) demonstrated a U-shaped curve for efficacy of ICD in primary prevention of SCD.

Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with left ventricular systolic dysfunction: 14 years after MADIT

Sudden cardiac death primary prevention trials Trial (year reported) Population Additional risk markers MADIT (1996) (20) 196 patients with MI longer Asymptomatic NSVT with than 3 weeks before entry inducible VT not and LVEF suppressed by IV [less than or equal to] procainamide 0.

Sudden cardiac death

As a result of these landmark findings from MADIT and other studies, the American College of Cardiology, the North American Society of Pacing and Electrophysiology, and the American Heart Association issued joint guidelines calling for expanded use of ICDs for the primary prevention of sudden cardiac death.

ICD--the beat goes on: experts call for expanded coverage of ICDs, the most effective method to date for preventing sudden cardiac death in high-risk coronary patients

The results of the MADIT II clinical trial, published earlier this year in the New England Journal of Medicine, demonstrated that placement of an ICD in patients with a prior myocardial infarction and a left ventricular ejection fraction of 30% or less resulted in a 5.

MTWA TESTING CAN DETERMINE WHO SHOULD RECEIVE ICD

Finally, we excluded all subjects (n = 33) who had indications other than ischemia for placement of an ICD and studied the remaining 165 patients who represented the MADIT II population.

Ejection fraction and QRS width as predictors of event rates in patients with implantable cardioverter defibrillators

Not only can device therapy provide a reduction in the risk of sudden death--and that is what the MADIT II trial was all about--but it can also alleviate symptoms.

Preserving the rhythm of life: leading heart experts call for broader use of implantable defibrillator technology that is improving and saving the lives of heart attack survivors

Previous trials, including MADIT, MUSTT and AVID, have demonstrated that implantable defibrillators improve survival in other patient populations.

IMPLANTABLE DEFIBRILLATOR STUDY ENDS EARLY

Arthur Moss, lead investigator of the MADIT II trail, to learn more about the study and its potential in saving the lives of high-risk heart patients, like Joe Lepley and Vice President Dick Cheney.

New hope for heart attack survivors: recent data from a landmark trial show that implantable cardioverter defibrillators help prolong the lives of people who have had heart attacks

Results from the MADIT II trial, involving more than 1,200 patients with impaired left ventricular function after MI, were released 2 years ago.

Lower risk, less benefit from ICD

While many studies over the years have demonstrated the benefits of ICDs, the MADIT II trial of 1,232 patients convincingly showed the benefits of ICDs implanted in patients who had a prior heart attack and an ejection fraction of less than 30 percent.

New hope for heart attack survivors. (Neighborhood Heart Watch)

This group of patients is outside of the MADIT II and SCDHeFT populations as the study included only patients with a left ventricular ejection fraction (LVEF) greater than or equal to 0.

Largest Prospective Study of Microvolt T-Wave Alternans Demonstrates This Technology's Predictive Value for Sudden Cardiac Death in Patients With Preserved Left Ventricular Function After Acute Myocardial Infarction

For example, evidence from MADIT II (the second Multicenter Automatic Defibrillator Implantation Trial) elevated the recommendation--that implantable cardiac defibrillators (ICDs) be used for primary prevention of sudden cardiac arrest in patients who have ischemic cardiomyopathy due to prior MI, have a left ventricular ejection fraction of less than 30%, and are New York Heart Association functional class I--from a class IIa recommendation ("it is reasonable") to a class I recommendation (it "should be performed/administered").